Abstract
Chemoresistance remains the major obstacle to successful therapy of cancer. In order to understand the mechanism of multidrug resistance (MDR) that is frequently observed in lung cancer patients, here we studied the contribution of MDR-related proteins by establishing lung cancer cell lines with acquired resistance against etoposide. We found that human H460 lung cancer cells responded to etoposide more sensitively than A549 cells. Among MDR-related proteins, the expression of p-glycoprotein (Pgp) and lung resistance protein (LRP) were much higher in A549 cells compared with that in H460 cells. When we established H460-R1 and-R2 cell lines by progressive exposure of H460 cells to increasing doses of etoposide, the response against etoposide as well as doxorubicin was greatly reduced in R1 and R2 cells, suggesting MDR induction. Induction of MDR was not accompanied by a decrease in the intracellular accumulation of etoposide and the expression of MDR-related proteins that function as drug efflux pumps such as Pgp and MRP1 was not changed. We found that the acquired resistance paralleled an increased expression of LRP in H460 cells. Taken together, our data suggest the implicative role of LRP in mediating MDR in lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aita, P., Robieux, I., Sorio, R., Tumolo, S., Corona, G., Cannizzaro, R., Colussi, A. M., Boiocchi, M. and Toffoli, G., Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.Cancer Chemother. Pharmacol., 43, 287–294 (1999).
Berger, W., Elbling, L., and Micksche, M., Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs.Int. J. Cancer, 88, 293–300 (2000).
Berger, W., Spiegl-Kreinecker, S., Buchroithner, J., Elbling, L., Pirker, C., Fischer, J., and Micksche, M., Overexpression of the human major vault protein in astrocytic brain tumor cells.Int. J. Cancer, 94, 377–382 (2001).
Borst, P., Evers, R., Kool, M., and Wijnholds, J., A family of drug transporters: the multidrug resistance-associated proteins.J. Natl. Cancer Inst., 92, 1295–1302 (2000).
Dingemans, A. M., van Ark-Otte, J., van der Valk, P., Apolinario, R. M., Scheper, R. J., Postmus, P. E., and Giaccone, G., Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues.Ann. Oncol., 7, 625–630 (1996).
Filipits, M., Pohl, G., Stranzl, T., Suchomel, R. W., Scheper, R. J., Jager, U., Geissler, K., Lechner, K., and Pirker, R., Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia.Blood, 91, 1508–1513 (1998).
Hu, Y., Stephen, A. G., Cao, J., Tanzer, L. R., Slapak, C. A., Harrison, S. D., Devanarayan, V., Dantzig, A. H., Starling, J. J., Rome, L. H., and Moore, R. E., A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells.Int. J. Cancer, 97, 149–156 (2002).
Ihde, D. C. and Minna, J. D., Non-small cell lung cancer. Part II: Treatment.Curr Probl Cancer, 15, 105–154 (1991).
Izquierdo, M. A., Scheffer, G. L., Flens, M. J., Shoemaker, R. H., Rome, L. H., and Scheper, R. J., Relationship of LRP-human major vault protein toin vitro and clinical resistance to anticancer drugs.Cytotechnology, 19, 191–197 (1996).
Kang, Y. H., Lee, E., Youk, H. J., Kim, S. H., Lee, H. J., Park, Y. G., and Lim, S. J., Potentiation by alpha-tocopheryl succinate of the etoposide response in multidrug resistance protein 1-expressing glioblastoma cells.Cancer Lett., 217, 181–190 (2005).
Kitazono, M., Okumura, H., Ikeda, R., Sumizawa, T., Furukawa, T., Nagayama, S., Seto, K., Aikou, T., and Akiyama, S., Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells.Int. J. Cancer, 91, 126–131 (2001).
Kitazono, M., Sumizawa, T., Takebayashi, Y., Chen, Z. S., Furukawa, T., Nagayama, S., Tani, A., Takao, S., Aikou, T., and Akiyama, S., Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells.J. Natl. Cancer Inst., 91, 1647–1653 (1999).
Lee, E. m., Hong, S. H., Lee, Y. J., Kang, Y. H., Choi, K. C., Choi, S. H., Kim, I. H., and Lim, S. J., Liposome-complexed adenoviral gene transfer in cancer cells expressing various levels of coxsackievirus and adenovirus receptor.J. Cancer Res. Clin. Oncol., 132, 223–233 (2003).
Meschini, S., Marra, M., Calcabrini, A., Monti, E., Gariboldi, M., Dolfini, E., and Arancia, G., Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells.Toxicol. In Vitro, 16, 389–398 (2002).
Mossink, M. H., van Zon, A., Scheper, R. J., Sonneveld, P., and Wiemer, E. A., Vaults: a ribonucleoprotein particle involved in drug resistance?Oncogene, 22, 7458–7467 (2003).
Ohsawa, M., Ikura, Y., Fukushima, H., Shirai, N., Sugama, Y., Suekane, T., Hirayama, M., Hino, M., and Ueda, M., Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma.Oncology, 68, 422–431 (2005).
Rybarova, S., Hajdukova, M., Hodorova, I., Kocisova, M., Boor, A., Brabencova, E., Kasan, P., Biros, E., Mojzis, J., and Mirossay, L., Expression of the multidrug resistance-associated protein 1 (MRP1) and the lung resistance-related protein (LRP) in human lung cancer.Neoplasma, 51, 169–174 (2004).
Sawada, M., Nakashima, S., Kiyono, T., Nakagawa, M., Yamada, J., Yamakawa, H., Banno, Y., Shinoda, J., Nishimura, Y., Nozawa, Y., and Sakai, N., p53 regulates ceramide formation by neutral sphingomyelinase through reactive oxygen species in human glioma cells.Oncogene, 20, 1368–1378 (2001).
Scheper, R. J., Broxterman, H. J., Scheffer, G. L., Kaaijk, P., Dalton, W. S., van Heijningen, T. H., van Kalken, C. K., Slovak, M. L., de Vries, E. G., and van der Valk, P., Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.Cancer Res., 53, 1475–1479 (1993).
Sugimoto, Y., Tsukahara, S., Ishikawa, E., and Mitsuhashi, J., Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.Cancer Sci., 96, 457–465 (2005).
Troyano, A., Fernandez, C., Sancho, P., de Blas, E., and Aller, P., Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation.J. Biol. Chem., 276, 47107–47115 (2001).
Young, L. C., Campling, B. G., Cole, S. P., Deeley, R. G., and Gerlach, J. H., Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels.Clin. Cancer Res., 7, 1798–1804 (2001).
Zhang, Y., Gupta, A., Wang, H., Zhou, L., Vethanayagam, R. R., Unadkat, J. D., and Mao, Q., BCRP Transports Dipyridamole and is Inhibited by Calcium Channel Blockers.Pharm. Res., 22, 2023–2034 (2005).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, E., Lim, SJ. The association of increased lung resistance protein expression with acquired etoposide resistance in human H460 lung cancer cell lines. Arch Pharm Res 29, 1018–1023 (2006). https://doi.org/10.1007/BF02969286
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02969286